Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 4/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.46 |
| ▸ | GRM7 | Q14831 | 3/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29434614 | 1.00 | GRIN2B (0.53) | GRIN2BSIGMAR1DPP4MAPTPRMT5 | |
| Bicarbonate SCHEMBL2441660 | 0.98 | GRIN2B (0.51) | GRIN2BSIGMAR1DPP4MAPTPRMT5 | |
| Hydrochloric Acid SCHEMBL10493696 | 0.98 | GRIN2B (0.51) | GRIN2BSIGMAR1DPP4MAPTPRMT5 | |
| Bromide SCHEMBL9725911 | 0.98 | GRIN2B (0.51) | GRIN2BSIGMAR1DPP4MAPTPRMT5 | |
| Glycine SCHEMBL2438253 | 0.93 | GRIN2B (0.47) | GRIN2BSIGMAR1DPP4MAPTPRMT5 | |
| SCHEMBL1742836 | 0.88 | GRIN2B (0.62) | GRIN2BSIGMAR1DPP4PRMT5MTNR1A | |
| SCHEMBL13846495 | 0.84 | GRIN2B (0.55) | GRIN2BSIGMAR1DPP4MAPTPRMT5 | |
| SCHEMBL13981017 | 0.83 | MTNR1A (0.51) | GRIN2BSIGMAR1DPP4MAPTPRMT5 | |
| SCHEMBL29378921 | 0.83 | KDM1A (0.50) | GRIN2BSIGMAR1DPP4MAPTPRMT5 | |
| SCHEMBL399565 | 0.83 | KDM1A (0.50) | GRIN2BSIGMAR1DPP4MAPTPRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250208137-A1 | COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2025-06-26 | — | — | US | claimed |
| EP-4493273-A1 | COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES | Politechnika Wroclawska (PL) | 2025-01-22 | — | — | EP | claimed |
| US-20240360177-A1 | PEPTIDES WITH ANTIMICROBIAL ACTIVITIES | AIMMAX THERAPEUTICS, INC. | 2024-10-31 | — | — | US | claimed |
| EP-4396196-A1 | PEPTIDES WITH ANTIMICROBIAL ACTIVITIES | Aimmax Therapeutics, Inc. (US) | 2024-07-10 | — | — | EP | claimed |
| CN-117897394-A | Peptides with antimicrobial activity | 美商安满药物开发公司 | 2024-04-16 | — | — | CN | claimed |
| US-20240076317-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | SIXTH STREET LENDING PARTNERS | 2024-03-07 | — | — | US | claimed |
| WO-2023175356-A1 | COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES | POLITECHNIKA WROCLAWSKA (PL) | 2023-09-21 | — | — | WO | claimed |
| US-11661441-B2 | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof | APELLIS PHARMACEUTICALS, INC. (US) | 2023-05-30 | — | — | US | claimed |
| WO-2023034481-A1 | PEPTIDES WITH ANTIMICROBIAL ACTIVITIES | AIMMAX THERAPEUTICS, INC. (US) | 2023-03-09 | — | — | WO | claimed |
| EP-4105224-A1 | LONG-ACTING COMPSTATIN ANALOGS AND USES THEREOF | Apellis Pharmaceuticals, Inc. (US) | 2022-12-21 | — | — | EP | claimed |
| EP-1549333-A1 | COMPSTATIN ANALOGS WITH IMPROVED ACTIVITY | The Trustees of The University of Pennsylvania (US) | 2005-07-06 | — | — | EP | claimed |
| EP-0813544-B1 | BRADYKININ ANTAGONIST PEPTIDES INCORPORATING N-SUBSTITUTED GLYCINES | CORTECH INC (US) | 2004-10-27 | — | — | EP | claimed |
| WO-2004026328-A1 | COMPSTATIN ANALOGS WITH IMPROVED ACTIVITY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2004-04-01 | — | — | WO | claimed |
| EP-0914158-A2 | PHARMACEUTICAL COMBINATION CONTAINING A COMPOUND HAVING ANGIOTENSIN II AND ANTAGONISTIC ACTIVITY | Takeda Chemical Industries, Ltd. (JP) | 1999-05-12 | — | — | EP | claimed |
| US-5750506-A | TREATING INFLAMMATION, HEAD TRAUMA, PAIN, ASTHMA | CORTECH, INC. (US) | 1998-05-12 | — | — | US | claimed |
| EP-0813544-A4 | — | — | 1998-01-07 | — | — | EP | claimed |
| EP-0813544-A1 | BRADYKININ ANTAGONIST PEPTIDES INCORPORATING N-SUBSTITUTED GLYCINES | CORTECH, INC. (US) | 1997-12-29 | — | — | EP | claimed |
| WO-1997037688-A2 | PHARMACEUTICAL COMBINATION CONTAINING A COMPOUND HAVING ANGIOTENSIN II AND ANTAGONISTIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-10-16 | — | — | WO | claimed |
| US-5610140-A | ANALGESICS, ANTIINFLAMMTORY AGENTS; TREATMENT OF ASTHMA | CORTECH, INC. (US) | 1997-03-11 | — | — | US | claimed |
| WO-1995024422-A1 | BRADYKININ ANTAGONIST PEPTIDES INCORPORATING N-SUBSTITUTED GLYCINES | CORTECH, INC. (US) | 1995-09-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11661441-B2 | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof | C3AR1, C5AR1, SERPINC1 | GRIN2B 3956/4885SIGMAR1 3800/4885DPP4 385/4885 |
| US-20240076317-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | C3AR1, C5AR1, SERPINC1 | GRIN2B 3956/4885SIGMAR1 3800/4885DPP4 385/4885 |
| US-20250208137-A1 | COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES | F11, F2, F12 | GRIN2B 4589/4885SIGMAR1 4663/4885DPP4 243/4885 |
| US-20240360177-A1 | PEPTIDES WITH ANTIMICROBIAL ACTIVITIES | VIP, FPR2, FPR1 | GRIN2B 2688/4885SIGMAR1 924/4885DPP4 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.